002294 信立泰
已收盘 08-16 15:00:00
资讯
新帖
简况
信立泰获得发明专利授权：“一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法”
证券之星 · 08-07
信立泰获得发明专利授权：“一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法”
深公司早报｜荣耀称四季度将进行股份制改革，适时启动IPO；信立泰子公司创新药临床试验获批；佰维存储独立董事辞职
21世纪经济报道 · 08-06
深公司早报｜荣耀称四季度将进行股份制改革，适时启动IPO；信立泰子公司创新药临床试验获批；佰维存储独立董事辞职
信立泰最新公告：抗肿瘤药JK06获批欧洲I期临床
证券之星 · 08-05
信立泰最新公告：抗肿瘤药JK06获批欧洲I期临床
信立泰(002294.SZ)：抗肿瘤生物药JK06获批在欧洲开展I期临床研究
智通财经网 · 08-05
信立泰(002294.SZ)：抗肿瘤生物药JK06获批在欧洲开展I期临床研究
信立泰最新公告：恩那度司他新适应症获得临床试验批准通知书
证券之星 · 07-31
信立泰最新公告：恩那度司他新适应症获得临床试验批准通知书
信立泰(002294.SZ)：恩那度司他新适应症获临床试验批准
智通财经 · 07-31
信立泰(002294.SZ)：恩那度司他新适应症获临床试验批准
信立泰最新公告：SAL0120获得临床试验批准通知书
证券之星 · 07-30
信立泰最新公告：SAL0120获得临床试验批准通知书
信立泰(002294.SZ)：SAL0120片获批开展治疗慢性肾脏病(CKD)的临床试验
智通财经 · 07-30
信立泰(002294.SZ)：SAL0120片获批开展治疗慢性肾脏病(CKD)的临床试验
信立泰最新公告：苯甲酸福格列汀片（信立汀）获得药品注册证书
证券之星 · 07-05
信立泰最新公告：苯甲酸福格列汀片（信立汀）获得药品注册证书
信立泰(002294.SZ)：苯甲酸福格列汀片(信立汀)获得药品注册证书
智通财经 · 07-05
信立泰(002294.SZ)：苯甲酸福格列汀片(信立汀)获得药品注册证书
信立泰（002294）6月28日主力资金净卖出410.50万元
证券之星 · 07-01
信立泰（002294）6月28日主力资金净卖出410.50万元
信立泰最新公告：SAL056上市申请获受理
证券之星 · 06-25
信立泰最新公告：SAL056上市申请获受理
信立泰(002294.SZ)：“注射用特立帕肽”上市申请获受理
智通财经 · 06-25
信立泰(002294.SZ)：“注射用特立帕肽”上市申请获受理
信立泰（002294）6月18日主力资金净买入585.67万元
证券之星 · 06-19
信立泰（002294）6月18日主力资金净买入585.67万元
信立泰公布国际专利申请：“一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途”
证券之星 · 06-16
信立泰公布国际专利申请：“一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途”
信立泰（002294）6月13日主力资金净卖出930.63万元
证券之星 · 06-14
信立泰（002294）6月13日主力资金净卖出930.63万元
信立泰最新公告：2023年年度权益分派10派5元 股权登记日6月18日
证券之星 · 06-11
信立泰最新公告：2023年年度权益分派10派5元 股权登记日6月18日
信立泰(002294.SZ)2023年年度权益分派：每10股派5元 6月18日股权登记
智通财经网 · 06-11
信立泰(002294.SZ)2023年年度权益分派：每10股派5元 6月18日股权登记
信立泰（002294）6月7日主力资金净卖出697.14万元
证券之星 · 06-11
信立泰（002294）6月7日主力资金净卖出697.14万元
信立泰（002294）6月4日主力资金净买入209.82万元
证券之星 · 06-05
信立泰（002294）6月4日主力资金净买入209.82万元
加载更多
公司概况
公司名称：
深圳信立泰药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-09-10
主营业务：
深圳信立泰药业股份有限公司主营业务是药品、医疗器械产品的研发、生产、销售。主要产品心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物等。
发行价格：
41.98
{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":28.71,"timestamp":1723791822000,"preClose":28.66,"halted":0,"volume":2064401,"delay":0,"floatShares":1115000000,"shares":1115000000,"eps":0.5108,"marketStatus":"已收盘","marketStatusCode":5,"change":0.05,"latestTime":"08-16 15:00:00","open":28.75,"high":28.8,"low":28.41,"amount":59147300,"amplitude":0.0136,"askPrice":28.74,"askSize":15,"bidPrice":28.71,"bidSize":19,"shortable":0,"etf":0,"ttmEps":0.5108,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724031000000},"adr":0,"adjPreClose":28.66,"symbolType":"stock","openAndCloseTimeList":[[1723771800000,1723779000000],[1723784400000,1723791600000]],"highLimit":31.53,"lowLimit":25.79,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"pbRate":3.88,"roa":"--","roe":"2.47%","epsLYR":0.52,"committee":-0.776382,"marketValue":32006000000,"floatMarketCap":31999000000,"peRate":56.205951,"changeRate":0.0017,"turnoverRate":0.0019,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2024-08-19。"},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2457652077","title":"信立泰获得发明专利授权：“一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2457652077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457652077?lang=zh_cn&edition=full","pubTime":"2024-08-07 02:31","pubTimestamp":1722969072,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示信立泰新获得一项发明专利授权，专利名为“一种手性3-丙酸的制备方法”，专利申请号为CN202110797895.6，授权日为2024年8月6日。专利摘要：本发明属于化学合成制备技术领域，具体涉及一种手性3丙酸的制备方法。今年以来信立泰新获得专利授权15个，较去年同期增加了7.14%。结合公司2023年年报财务数据，2023年公司在研发方面投入了4.09亿元，同比减23.34%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080700003419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0239","BK0196","BK0188","002294","BK0183"],"gpt_icon":0},{"id":"2457051224","title":"深公司早报｜荣耀称四季度将进行股份制改革，适时启动IPO；信立泰子公司创新药临床试验获批；佰维存储独立董事辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2457051224","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457051224?lang=zh_cn&edition=full","pubTime":"2024-08-06 11:05","pubTimestamp":1722913500,"startTime":"0","endTime":"0","summary":"辞任后，陈新先生不再担任公司任何职务。由于陈新先生辞职将导致公司独立董事占董事会成员的比例低于三分之一，陈新先生的辞职将在公司召开股东大会选举产生新任独立董事后生效。荣耀计划在今年四季度启动相应的股份制改革，并在之后适时启动IPO流程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061115379f12449d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061115379f12449d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0214","BK0187","BK0028","159992","002294","BK0188","BK0239","BK0183","BK0196","688525"],"gpt_icon":0},{"id":"2457743091","title":"信立泰最新公告：抗肿瘤药JK06获批欧洲I期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2457743091","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457743091?lang=zh_cn&edition=full","pubTime":"2024-08-05 16:37","pubTimestamp":1722847029,"startTime":"0","endTime":"0","summary":"信立泰公告，公司子公司SalubrisBio自主研发的广谱抗肿瘤创新生物药JK06已获批可在欧洲部分国家开展I期临床研究。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080500021137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","BK0187","BK0183","002294","BK0028"],"gpt_icon":0},{"id":"2457717356","title":"信立泰(002294.SZ)：抗肿瘤生物药JK06获批在欧洲开展I期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2457717356","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457717356?lang=zh_cn&edition=full","pubTime":"2024-08-05 15:47","pubTimestamp":1722844067,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)发布公告，公司收到子公司美国Salubris \nBio...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/17.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/17.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1159923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0183","BK0028","BK0188","BK0239","002294","159839","BK0187","BK0196"],"gpt_icon":0},{"id":"2455184259","title":"信立泰最新公告：恩那度司他新适应症获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2455184259","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455184259?lang=zh_cn&edition=full","pubTime":"2024-07-31 19:29","pubTimestamp":1722425396,"startTime":"0","endTime":"0","summary":"信立泰公告，近日，公司收到国家药监局核准签发的《临床试验批准通知书》，同意公司的恩那度司他片开展新适应症（治疗非髓系恶性肿瘤患者化疗引起的贫血，简称“CIA”）的临床试验。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100040736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0187","BK1576","BK1583","BK0196","BK0188","03347","BK1141","BK0183","002294","BK0028"],"gpt_icon":0},{"id":"2455218506","title":"信立泰(002294.SZ)：恩那度司他新适应症获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2455218506","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455218506?lang=zh_cn&edition=full","pubTime":"2024-07-31 18:55","pubTimestamp":1722423326,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司的恩那度司他片开展新适应症(治疗非髓系恶性肿瘤患者化疗引起的贫血，即“CIA”)的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1158167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK1576","BK0028","BK0183","BK0239","BK1141","BK1583","03347","BK0188","002294","BK0196"],"gpt_icon":0},{"id":"2455939412","title":"信立泰最新公告：SAL0120获得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2455939412","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455939412?lang=zh_cn&edition=full","pubTime":"2024-07-30 20:30","pubTimestamp":1722342641,"startTime":"0","endTime":"0","summary":"信立泰公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0120片开展治疗慢性肾脏病（CKD）的临床试验。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073000041249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","002294","BK0188","BK0239","BK1576","BK0028","BK1141","BK1583","03347","BK0183","BK0196"],"gpt_icon":0},{"id":"2455293957","title":"信立泰(002294.SZ)：SAL0120片获批开展治疗慢性肾脏病(CKD)的临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2455293957","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455293957?lang=zh_cn&edition=full","pubTime":"2024-07-30 20:27","pubTimestamp":1722342428,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0120片(项目代码：SAL0120)开展治疗慢性肾脏病(CKD)的临床试验。SAL0120是公司自主研发的小分子ETA受体拮抗剂，拟开发适应症包括CKD、IgA肾病及高血压等。目前正在启动高血压II期临床试验，进展顺利。SAL0120若能研发成功并获批上市，将有望进一步丰富公司慢病领域的创新产品管线，为高血压患者及肾病患者提供新的选择，满足未被满足的临床需求，提升公司核心竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1157629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK0028","BK1576","03347","BK0239","BK0187","002294","BK0183","BK1141","BK0196","BK0188"],"gpt_icon":0},{"id":"2449253466","title":"信立泰最新公告：苯甲酸福格列汀片（信立汀）获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449253466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449253466?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:24","pubTimestamp":1720167846,"startTime":"0","endTime":"0","summary":"信立泰公告，近日，公司收到国家药品监督管理局核准签发的苯甲酸福格列汀片（商品名：信立汀）药品注册证书。苯甲酸福格列汀片（信立汀）是一种二肽基肽酶4（DPP-4）抑制剂，用于改善成人2型糖尿病患者的血糖控制。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500030131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0028","BK0188","BK0239","002294","BK0196","BK0187"],"gpt_icon":0},{"id":"2449230295","title":"信立泰(002294.SZ)：苯甲酸福格列汀片(信立汀)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449230295","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449230295?lang=zh_cn&edition=full","pubTime":"2024-07-05 15:59","pubTimestamp":1720166386,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的苯甲酸福格列汀片(商品名：信立汀)药品注册证书。据悉，苯甲酸福格列汀片(信立汀)是一种二肽基肽酶4(DPP-4)抑制剂，用于改善成人2型糖尿病患者的血糖控制(包括单药治疗，以及单独使用盐酸二甲双胍不能有效控制血糖时的联合治疗)，为国产1类创新药(项目代码：SAL067)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0239","BK0188","BK0187","BK0183","002294","BK0028"],"gpt_icon":0},{"id":"2448933413","title":"信立泰（002294）6月28日主力资金净卖出410.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448933413","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448933413?lang=zh_cn&edition=full","pubTime":"2024-07-01 09:23","pubTimestamp":1719797032,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月28日收盘，信立泰报收于26.63元，下跌1.92%，换手率0.3%，成交量3.36万手，成交额9030.83万元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入1063.08万元，融资偿还746.93万元，融资净买入316.15万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100003762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0028","BK0183","BK0239","BK0188","002294","BK0196"],"gpt_icon":0},{"id":"2446099899","title":"信立泰最新公告：SAL056上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2446099899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446099899?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:35","pubTimestamp":1719304531,"startTime":"0","endTime":"0","summary":"信立泰公告，子公司信立泰(苏州)药业有限公司的生物药“注射用特立帕肽”(SAL056)申报上市申请获得国家药品监督管理局受理。SAL056是长效骨形成促进剂，每周一次皮下注射，拟用于治疗有骨折高发风险的绝经后妇女骨质疏松症。目前国内尚无同规格及用法用量的产品。若获批上市，将大幅提高患者用药便利性。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500030973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0187","002294","BK0183","BK0196","BK0188"],"gpt_icon":0},{"id":"2446962198","title":"信立泰(002294.SZ)：“注射用特立帕肽”上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2446962198","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446962198?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:10","pubTimestamp":1719303046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司子公司信立泰(苏州)药业有限公司在研的生物药“注射用特立帕肽”(项目代码：SAL056)申报上市申请获得国家药品监督管理局受理，拟申请适应症为：治疗有骨折高发风险的绝经后妇女骨质疏松症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0028","BK0188","BK0239","BK0187","002294","BK0196"],"gpt_icon":0},{"id":"2444967784","title":"信立泰（002294）6月18日主力资金净买入585.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444967784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444967784?lang=zh_cn&edition=full","pubTime":"2024-06-19 09:04","pubTimestamp":1718759092,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月18日收盘，信立泰报收于27.95元，下跌1.55%，换手率0.29%，成交量3.18万手，成交额8933.3万元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入1129.08万元，融资偿还290.82万元，融资净买入838.25万元，连续3日净买入累计961.1万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900014403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","002294","BK0028","BK0196","BK0239","BK0188","BK0183"],"gpt_icon":0},{"id":"2443908849","title":"信立泰公布国际专利申请：“一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2443908849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443908849?lang=zh_cn&edition=full","pubTime":"2024-06-16 04:33","pubTimestamp":1718483609,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示信立泰公布了一项国际专利申请，专利名为“一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途”，专利申请号为PCT/CN2023/136923，国际公布日为2024年6月13日。专利详情如下：图片来源：世界知识产权组织今年以来信立泰已公布的国际专利申请5个，较去年同期增加了25%。结合公司2023年年报财务数据，2023年公司在研发方面投入了4.09亿元，同比减23.34%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061600000314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0196","159938","BK0239","BK1515","BK1574","BK0183","09939","002294","BK0028","BK0187","BK0188"],"gpt_icon":0},{"id":"2443661507","title":"信立泰（002294）6月13日主力资金净卖出930.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443661507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443661507?lang=zh_cn&edition=full","pubTime":"2024-06-14 09:12","pubTimestamp":1718327579,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月13日收盘，信立泰报收于28.94元，上涨3.88%，换手率0.71%，成交量7.92万手，成交额2.28亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入440.04万元，融资偿还2341.26万元，融资净偿还1901.22万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400012939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0187","BK0196","BK0188","BK0183","002294","BK0028"],"gpt_icon":0},{"id":"2442395257","title":"信立泰最新公告：2023年年度权益分派10派5元 股权登记日6月18日","url":"https://stock-news.laohu8.com/highlight/detail?id=2442395257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442395257?lang=zh_cn&edition=full","pubTime":"2024-06-11 20:49","pubTimestamp":1718110195,"startTime":"0","endTime":"0","summary":"信立泰公布2023年年度权益分派实施公告，公司2023年年度权益分派方案为：向全体股东每10股派5元人民币现金(含税)。本次权益分派股权登记日为：2024年6月18日，除权除息日为：2024年6月19日。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100029405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0187","BK0239","BK0196","BK0188","002294","BK0183"],"gpt_icon":0},{"id":"2442366629","title":"信立泰(002294.SZ)2023年年度权益分派：每10股派5元 6月18日股权登记","url":"https://stock-news.laohu8.com/highlight/detail?id=2442366629","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442366629?lang=zh_cn&edition=full","pubTime":"2024-06-11 18:38","pubTimestamp":1718102304,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)发布公告，公司2023年年度权益分派方案为：以公司现有...","market":"us","thumbnail":"https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK0187","BK0196","BK0239","002294","BK0183","BK0188"],"gpt_icon":0},{"id":"2442044478","title":"信立泰（002294）6月7日主力资金净卖出697.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442044478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2442044478?lang=zh_cn&edition=full","pubTime":"2024-06-11 09:22","pubTimestamp":1718068977,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月7日收盘，信立泰报收于27.26元，下跌1.77%，换手率0.31%，成交量3.44万手，成交额9440.26万元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入598.47万元，融资偿还1086.93万元，融资净偿还488.46万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100002304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0183","BK0187","BK0239","BK0196","002294"],"gpt_icon":0},{"id":"2441295847","title":"信立泰（002294）6月4日主力资金净买入209.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441295847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441295847?lang=zh_cn&edition=full","pubTime":"2024-06-05 09:17","pubTimestamp":1717550236,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月4日收盘，信立泰报收于27.75元，上涨2.55%，换手率0.4%，成交量4.43万手，成交额1.22亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入872.5万元，融资偿还1333.69万元，融资净偿还461.19万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060500015529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","BK0183","BK0188","BK0239","002294","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","stockEarnings":[{"period":"1week","weight":0.0067},{"period":"1month","weight":0.0152},{"period":"3month","weight":-0.0111},{"period":"6month","weight":-0.0552},{"period":"1year","weight":0.0315},{"period":"ytd","weight":-0.1049}],"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","perCapita":"41336股","boardName":"医药制造业","registeredCapital":"111481万元","compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0282},{"period":"3month","weight":-0.0871},{"period":"6month","weight":0.0047},{"period":"1year","weight":-0.0899},{"period":"ytd","weight":-0.0321}],"survey":" 深圳信立泰药业股份有限公司主营业务是药品、医疗器械产品的研发、生产、销售。主要产品心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物等。","serverTime":1723874372084,"listedPrice":41.98,"stockholders":"26963人(较上一季度减少2.58%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}